Clinical Trials Logo

Bone Marrow Diseases clinical trials

View clinical trials related to Bone Marrow Diseases.

Filter by:

NCT ID: NCT05006495 Completed - Neck Pain Clinical Trials

Comparison Between C3-6 Laminoplasty and C3 Laminectomy With Cervical Laminoplasty

Start date: March 20, 2017
Phase: N/A
Study type: Interventional

Investigators performed a prospective randomized controlled trial for comparing postoperative clinical and radiological outcomes between C3 laminectomy with laminoplasty and C3-6 laminoplasty.

NCT ID: NCT04968639 Recruiting - Cervical Myelopathy Clinical Trials

The Characteristic of Axial Pain and EEG Analysis of Patients After Laminoplasty

Start date: January 1, 2019
Phase:
Study type: Observational

The characteristic of axial pain and EEG analysis of patients after laminoplasty

NCT ID: NCT04968028 Recruiting - Clinical trials for Cervical Spondylosis With Myelopathy

Multi-centre Study to Evaluate ACAF Versus Laminoplasty in Treating Cervical Ossification of the Posterior Longitudinal Ligament

Start date: August 17, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the efficacy, safety and imaging outcomes between Anterior Controllable Antedisplacement and Fusion (ACAF) and Laminoplasty in the treatment of severe ossification of cervical posterior longitudinal ligament.

NCT ID: NCT04962256 Completed - Cervical Myelopathy Clinical Trials

ERAS in Posterior Approach of Cervical Spine Operation

Start date: March 20, 2019
Phase:
Study type: Observational

Enhanced recovery after surgery (ERAS) strategy has been used in the patient management of different diseases. This study aims to evaluate the effectiveness of ERAS in the perioperative period of posterior approach of cervical spine operation among patients with CSM.

NCT ID: NCT04955041 Active, not recruiting - Clinical trials for Cervical Spondylotic Myelopathy

Effectiveness of T2* MRI in Cervical Spondylotic Myelopathy

Start date: January 2010
Phase:
Study type: Observational

Utilization of T2* MRI in predicting prognosis in patients with cervical spondylotic myelopathy (CSM)

NCT ID: NCT04952831 Enrolling by invitation - Clinical trials for Cervical Spondylotic Myelopathy

Diffusion MRI in Cervical Spondylotic Myelopathy

Start date: September 1, 2020
Phase:
Study type: Observational

diffusion MRI in evaluates and predicts prognosis in CSM

NCT ID: NCT04947891 Completed - Cervical Myelopathy Clinical Trials

The Establishment of the Integration of Surgery and Postoperative Intensive Recovery of Patients With CSM

Start date: December 6, 2017
Phase:
Study type: Observational

This study aims to establish the specialist consensus of the integration of posterior approach surgical treatment and postoperative intensive recovery management for CSM or OPLL patients, and verify its safety, practicability and reliability.

NCT ID: NCT04947280 Recruiting - Breast Cancer Clinical Trials

Single Arm Phase II Study of Fractionated Stereotatic Radiation Therapy (FSRT) for Bone Metastases in Breast Cancer

Start date: January 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Fractionated stereotatic radiation therapy (FSRT) that very precisely delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. The purpose of this study is to find out if FSRT is safe and effective in the treatment of metastatic spinal tumors of breast cancer.

NCT ID: NCT04936074 Recruiting - Clinical trials for Cervical Spondylotic Myelopathy

Fusion or no Fusion After Decompression of the Spinal Cord in Patients With Degenerative Cervical Myelopathy

MyRanC
Start date: February 21, 2022
Phase: N/A
Study type: Interventional

Background: Degenerative cervical myelopathy (DCM) is characterized by neck pain, neck stiffness, weakness, paresthesia, sphincter disturbance and balance disorder. The mean age for symptoms is 64 years and more men than women, 2.7:1, are affected. The most common level is C5-C6. DCM is the predominant cause of spinal cord dysfunction in the elderly worldwide. Surgical options include stand-alone laminectomy, laminectomy and fusion and laminoplasty. The preferable surgical approach is though, a matter of controversy. The objective of this study is to compare stand-alone laminectomy to laminectomy and fusion. Methods/Design: This is a multicenter randomized, controlled, parallel group non-inferiority trial. A total of 300 adult participants are allocated in a ratio of 1:1. The primary endpoint is reoperation for any reason within 5 years of follow-up. Sample size and power calculations were performed by estimating the reoperation rate after laminectomy to 3.4% and after laminectomy with fusion to 7.9% based on data from the Swedish spine registry (Swespine) on patients with DCM. Secondary outcomes are the patient derived modified Japanese orthopaedic association (P-mJOA) score, Neck disability index (NDI), European quality of life five dimensions (EQ-5D), Numeric rating scale (NRS) for neck and arm pain, Hospital anxiety and depression scale (HADS), development of kyphosis measured as the cervical sagittal vertical axis (cSVA) and, death. Clinical and radiological follow-up is performed at 3, 12, 24 and 60 months after surgery. The main inclusion criteria is 1-4 levels of DCM in the subaxial spine, C3-C7, with or without deformity. The REDcap will be used for safe data management. Data will be analyzed in the per protocol (PP) population, defined as randomized patients who are still alive without having emigrated or left the study after five years. Discussion: This will be the first randomized controlled trial comparing two of the most common surgical treatments for DCM; the posterior muscle-preserving selective laminectomy and posterior laminectomy with instrumented fusion. The results of the MyRanC study will provide surgical treatment recommendations for DCM. This may result in improvements in surgical treatment and clinical practice regarding DCM.

NCT ID: NCT04894734 Recruiting - Clinical trials for Spinal Cord Injury at T1-T12 Level

Spinal Cord Stimulation (SCS) for Spinal Cord Injury (SCI)

Start date: December 30, 2021
Phase: N/A
Study type: Interventional

The purpose of this feasibility study is to compare the impact of Spinal cord stimulation [SCS] for Spinal Cord Injury (SCI) pain and rehabilitation. SCS, also known as Epidural Electrical Stimulation (EES), will be utilized along with conventional medical management (CMM) or CMM alone. Participation in this research study is expected to last approximately 12 months. All subjects will be evaluated and proceed with implantation of two SCS devices- one tailored based on the individual's SCI for the treatment of neuropathic pain of trunk and limb and a second near the bottom of the spinal cord (conus region) to study the impact on motor, sensory, bowel/bladder outcomes. All patients will also continue receiving CMM, such as medications and physical therapy. Participating subjects will be randomly assigned to one of two treatment groups: 1. Placebo arm: SCS OFF + CMM. Under the direction of the study physician, the patient may receive a variety of treatments, such as medications and various forms of rehabilitation. 2. Treatment arm: SCS ON + CMM. The study treatment Spinal Cord Stimulation [SCS]: the study physician will perform a trial procedure to see if the study procedure works for the patient and may implant a permanent device if it is successful. There is a temporary trial procedure, or a "test drive," which usually lasts 5-7 days. If this is successful, patients will discuss a more permanent implant. This study involves the concurrent placement of two SCS devices (one focused on pain and the second for rehabilitation). For three months, treatment group subjects will have the SCS turned on and will have rehabilitation as part of their CMM. Participants in the placebo arm will have their SCS remain off and will undergo CMM with rehabilitation therapy similar to the treatment group. Neither the subjects nor the treatment team will know which patients are in the treatment or placebo arm. At the end of three months, the study group will be revealed and the placebo group subjects will be allowed to crossover and have their SCS turned on. Rehabilitation visits may be remote and the study duration is approximately 12 months. There may be additional blood tests and clinical exams to collect data on the effectiveness of the therapy. Data at follow-up visits will be compared to the subjects' baseline data and that of the control group at the respective visits.